Gentile A, et al. Influenza in Latin America: A report from the Global Influenza Initiative (GII). Vaccine. 2019 Apr 8. pii: S0264-410X(19)30436-0
The Global Influenza Initiative (GII) is a global expert group that aims to raise acceptance and uptake of influenza vaccines globally and provides recommendations and strategies to address challenges at local, national, regional, and global levels. This article provides a consolidated estimation of disease burden in Latin America, currently lacking in published literature, and delivers the GII recommendations specific to Latin America that provide guidance to combat existing vaccination challenges. While many countries worldwide, especially in the tropics and subtropics, do not have a seasonal influenza policy, 90% of Latin American countries have a seasonal influenza policy in place. Local governments in the Latin American countries and The Pan American Health Organization´s Technical Advisory Group on Vaccine-preventable Diseases play a major role in improving the vaccination coverage and reducing the overall disease burden. Influenza seasonality poses the biggest challenge in deciding on optimal timing for vaccination in Latin America, as in temperate climates seasonal influenza activity peaks during the winter months (November-February and May-October) in the northern and southern hemispheres, respectively, while in the tropics and subtropical regions it usually occurs throughout the year, but especially during the rainy season. Besides this, vaccine mismatch with circulating strains, misconception concerning influenza vaccine effectiveness, and poor disease and vaccine awareness among the public are also key challenges that need to be overcome. Standardization of clinical case definitions is important across all Latin American countries. Surveillance (mostly passive) has improved substantially in the Latin American countries over the past decade, but more is still required to better understand the disease burden and help inform policies.
See Also:
Latest articles in those days:
- Nomenclature Updates to the Hemagglutinin Gene Clade Designations Resulting From the Continued Evolution of High Pathogenicity Avian Influenza A(H5) Virus Clades 2.3.2.1c and 2.3.4.4 12 hours ago
- Mathematical modeling of in vitro replication dynamics for multiple highly pathogenic avian influenza clade 2.3.4.4 viruses in chicken and duck cells 12 hours ago
- H5 influenza virus mRNA-lipid nanoparticle (LNP) vaccination elicits adaptive immune responses in Holstein calves 12 hours ago
- Highly pathogenic avian influenza as a systemic risk - implications for control and preparedness 2 days ago
- Multiple introductions and spread of novel reassortant highly pathogenic avian influenza A (H5N1) clade 2.3.4.4b viruses via wild birds, South Korea, 2024-2025 2 days ago
[Go Top] [Close Window]


